{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:26Z","timestamp":1790983166481,"version":"4.1.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>Rosuvastatin, a hydrophilic statin, is generally considered to have a low risk of clinically significant interactions with macrolide antibiotics, and concurrent use with clarithromycin is not contraindicated according to NHS Specialist Pharmacy Service guidance. However, rare cases of severe toxicity have been reported, particularly in the elderly or critically ill patients. A 69-year-old male, with a past medical history of ischemic heart disease developed marked transaminase elevation followed by severe rhabdomyolysis after receiving high-dose rosuvastatin concurrently with clarithromycin for a lower respiratory tract infection. Withdrawal of both agents, along with supportive treatment with intravenous N-acetylcysteine and ursodeoxycholic acid led to a rapid biochemical improvement. The patient subsequently died due to refractory shock related to his critical illness, and death was not directly attributed to the suspected drug\u2013drug interaction. This case highlights a rare but clinically important interaction between rosuvastatin and macrolides that may be under-recognized, particularly in the elderly or critically ill patients.<\/jats:p>","DOI":"10.4103\/ijp.ijp_96_26","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:00:23Z","timestamp":1782410423000},"page":"481-483","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A rare rosuvastatin\u2013clarithromycin interaction presenting with acute liver injury and delayed rhabdomyolysis"],"prefix":"10.4103","volume":"58","author":[{"given":"Nithin Tumkur","family":"Prasad","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Apollo Specialty Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"R1-20260626","first-page":"e1082","article-title":"2018 ACC\/AHA guideline on the management of blood cholesterol","volume":"139","author":"Stone","year":"2019","journal-title":"Circulation"},{"key":"R2-20260626","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R3-20260626","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"The National Lipid Association's Safety Task Force. A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R4-20260626","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/TCRM.S214938","article-title":"The clinical significance of statins-macrolides interaction: Comprehensive review of in vivo studies, case reports, and population studies","volume":"15","author":"Abu Mellal","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"R5-20260626","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","article-title":"Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"R6-20260626","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7326\/0003-4819-158-12-201306180-00004","article-title":"Statin toxicity from macrolide antibiotic coprescription: A population-based cohort study","volume":"158","author":"Patel","year":"2013","journal-title":"Ann Intern Med"},{"key":"R7-20260626","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20260626","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_96_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:25:53Z","timestamp":1787747153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_96_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_96_26","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-01-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}